Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742817 · ClinicalTrials.gov registry record · NA
Effects of e-Cigarettes on Perceptions and Behavior
A NA study of Electronic Cigarettes, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT03742817: Completed NA study of Electronic Cigarettes, sponsored by University of Southern California.
NCT03742817 is a NA study of Electronic Cigarettes that has completed, run by University of Southern California. The registered enrollment target is 45 participants, above the 35-participant average among 3 other Electronic Cigarettes trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742817, a NA study of Electronic Cigarettes, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will assess the ways in which e-cigarette product diversity impacts the user experience to inform potential regulations by identifying product characteristics that may: (1) put young adults at risk for tobacco product use; and (2) facilitate adult smokers switching to e-cigarettes. There are three primary objectives to the study: (1) Determine which dimensions of e-cigarette product diversity differentially affect product appeal across young adult e-cigarette users and middle-age/older adult smokers with an interest in, but no significant experience with, e-cigarettes; (2) Determine which dimensions of e-cigarette product diversity differentially affect abuse liability in young adult e-cigarette users and the ability to resist smoking in adult smokers with an interest in, but no significant experience with, e-cigarettes; (3) Determine the affect of product characteristics on e-cigarette nicotine delivery profile. For Aim 1, young adult vapers (N=200) and adult smokers (N=200) will attend one laboratory session in which they will self-administer e-cigarette products varied according to within-subject e-cigarette factors (e.g., flavor, pg/vg ratio). For Aim 2, young adults vapers (N=360) and adult smokers (N=360) will administer an e-cigarette product and complete behavioral economic tasks that test the participant's choice of earning money to delay initiation and continued use of: (1) The sampled e-cigarette product (abuse liability; young adult vapers); or (2) Their own brand cigarettes (ability to resist smoking; adult current smokers). A pilot study will establish device and e-liquid parameters (e.g., nicotine concentration) to be used for all aims.
Primary Outcome
Self-report measures of product appeal will be completed following the e-cigarette administration.
Conditions Studied
Interventions
- OTHER e-Cigarette
Study Locations (1)
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2020-03-01 |
| Phase | NA |
What the finished NCT03742817 record still lists
NCT03742817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, above the 35-participant average among 3 other Electronic Cigarettes trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Electronic Cigarettes appearing as the primary indexed condition, and to 1 intervention - of which e-Cigarette is the first listed.
NCT03742817 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03742817 about?
NCT03742817 is a clinical study titled "Effects of e-Cigarettes on Perceptions and Behavior". This project will assess the ways in which e-cigarette product diversity impacts the user experience to inform potential regulations by identifying product characteristics that may: (1) put young adults at risk for tobacco product use; and (2) facilitate adult smokers switching to e-cigarettes. Ther...
What is the current status of trial NCT03742817?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2019-02-01. Estimated completion is 2020-03-01.
What conditions does trial NCT03742817 study?
This clinical trial studies the following conditions: Electronic Cigarettes.
What interventions are being tested in trial NCT03742817?
The interventions under investigation include: e-Cigarette (OTHER).
Who is sponsoring clinical trial NCT03742817?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03742817 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Electronic Cigarettes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI